In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genpharm Inc.

Division of Merck KGaA

Latest From Genpharm Inc.

Bristol/Medarex: A Transformational Acquisition Rooted In Collaboration

Bristol's $2.4 billion buyout of Medarex in 2009 yielded value equivalent or greater to that realized in larger M&A transactions signed that year, such as Pfizer/Wyeth, Merck/Schering-Plough and Roche/Genentech. The deal made BMS a leader in immuno-oncology and by most accounts is the highlight of the pharma's "string of pearls" strategy.

Deals Business Strategies

Altana Calls Trumps

The success of gastrointestinal drug pantoprazole has turned mid-sized Altana into one of Europe's fastest growing pharmaceutical companies. By re-investing the proceeds from pantoprazole into its own R&D, Altana now has two late-stage follow-ons--ciclesonide and roflumilast--with similar potential to pantoprazole. Rather than simply out-licensing these compounds to larger players, Altana wants a more active role alongside its partners in marketing and selling its own drugs, hoping thereby to establish itself internationally.
BioPharmaceutical Strategy

AstraZeneca: Bridging the Prilosec Earnings Gap

AstraZeneca appears to have navigated the integration process without much of the turmoil seen in other mergers. As part of that integration, the company created a new, centralized sales and marketing infrastructure intended to transform two mid-size European companies into a commercial global power. That new organization will soon confront the company's most immediate challenge: dealing with the genericization of the world's biggest drug, Prilosec. Whether AstraZeneca can meet that challenge will turn largely on the extent to which two late-stage drug candidates, Nexium and Crestor, can fill the Prilosec void. They'll require a commercialization effort far beyond that attempted by the former Astra or Zeneca.
BioPharmaceutical Strategy

Whither Generics? Five Opinions

A few years ago, generics looked unstoppable; today, pricing's reached suicidal levels. As for generic substitution, patients would rather fight than switch.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Merck KGaA
  • Senior Management
  • Ian Hilley, VP, Bus. Dev.
  • Contact Info
  • Genpharm Inc.
    Phone: (416) 236-2631
    85 Advance Road
    Etobicoke, M8Z 2S6